Tagraxofusp in myeloid malignancies

Hematol Oncol. 2024 Jan;42(1):e3234. doi: 10.1002/hon.3234. Epub 2023 Oct 17.

Abstract

Tagraxofusp (or SL-401) is a recombinant molecule composed of human interleukin-3 that binds CD123 on neoplastic cells fused to a truncated diphtheria toxin (DT). Tagraxofusp's most significant success has come from studies involving patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN), an aggressive disease that is usually refractory to conventional chemotherapy. Tagraxofusp had an acceptable safety profile and high efficacy in early phase I/II studies on patients with BPDCN. Another phase II study confirmed the good response rates, resulting in Food and Drugs Administration and European Medicine Agency approval of tagraxofusp for the treatment of BPDCN. Considering its high efficacy and its manageable safety profile, tagraxofusp has been suddenly explored in other myeloid malignancies with high expression of cell surface CD123, both in monotherapy or combination strategies. The triplet tagraxofusp-azacytidine-venetoclax appears to be of particular interest among these combinations. Furthermore, combination strategies may be used to overcome tagraxofusp resistance. The downregulation of DPH1 (diphthamide biosynthesis 1), the enzyme responsible for the conversion of histidine 715 on eEF2 to diphthamide, which is then the direct target of ADP ribosylation DT, is typically associated with this resistance phenomenon. It has been discovered that azacitidine can reverse DHP1 expression and restore sensitivity to tagraxofusp. In conclusion, the success of tagraxofusp in BPDCN paved the way for its application even in other CD123-positive malignancies. Nowadays, several ongoing trials are exploring the use of tagraxofusp in different myeloid neoplasms. This review aims to summarize the actual role of tagraxofusp in BPDCN and other CD123-positive myeloid malignancies.

Keywords: AML; BPDCN; CD123; myeloid malignancies; tagraxofusp.

Publication types

  • Review

MeSH terms

  • Acute Disease
  • Azacitidine / therapeutic use
  • Clinical Trials, Phase II as Topic
  • Dendritic Cells / pathology
  • Hematologic Neoplasms* / pathology
  • Humans
  • Interleukin-3 Receptor alpha Subunit / metabolism
  • Interleukin-3 Receptor alpha Subunit / therapeutic use
  • Myeloproliferative Disorders* / pathology
  • Recombinant Fusion Proteins*
  • Skin Neoplasms* / pathology

Substances

  • tagraxofusp
  • Interleukin-3 Receptor alpha Subunit
  • Azacitidine
  • Recombinant Fusion Proteins